Table 2 Improvement in DAS 28 and HAQ, and DAS-28-based EULAR response in patients switching between TNF antagonists
1st TNF antagonist | 2nd TNF antagonist | 3rd TNF antagonist | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Initial | Final | Δ | p | Initial | Final | Δ | p | Initial | Final | Δ | P | |
DAS-28 | 5.9 | 3.3 | -2.6 | <0.0001 | 5.1 | 4.2 | -1.1 | 0.0001 | 6.1 | 5.4 | -0.7 | 0.06 |
HAQ | 1.61 | 1.12 | -0.49 | <0.0001 | 1.52 | 1.31 | -0.21 | <0.004 | 1.87 | 1.75 | -0.12 | 0.1 |
Good (%)* | 174(42) | 17(20) | 5(28) | |||||||||
Moderate (%)* | 138(33) | 20(27) | ||||||||||
No response (%)* | 105(25) | 44(53) | 13(72) | |||||||||